UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2021

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation) 001-33185 (Commission File Number) 33-0927979 (I.R.S. Employer Identification No.)

4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA 92037

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (858) 373-1500

Not applicable.
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):					
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				
Securities registered pursuant to Section 12(b) of the Act:					

Common Stock,	, \$0.001 par value		MNOV	The Nasdag Stock Market LLC
(Title of e	each class)	(Trac	ling symbol(s))	(Name of each exchange on which registered)
		is an emerging growth con nge Act of 1934 (§240.12b		405 of the Securities Act of 1933 (§230.405 of this
	erging growth company			
		neck mark if the registrant ded pursuant to Section 13		extended transition period for complying with any new
Item 5.07 Submission	of Matters to a Vote o	f Security Holders.		
				5, 2021 (the "Annual Meeting"). The Company filed its and Exchange Commission on April 27, 2021 (the
outstanding. The holde	ers of a total of 37,078,1		k were present at the Anni	pany had 48,768,541 shares of common stock issued and ual Meeting, either in person or by proxy, which total g.
Set forth below	are the results of the ma	tters submitted for a vote o	of stockholders at the Ann	ual Meeting
successors h	ave been duly elected a		until their earlier death, re	eeting of stockholders and until their signation or removal. The named
Final Voting Results				
Nominees Yuichi Iwaki Kazuko Matsuda	For 25,380,059 31,086,138	Against 3,148,892 2,944,818	Abstain 5,982,489 480,484	Broker Non-Vote 2,566,698 2,566,698
				ng firm of the Company for the con at the Annual Meeting as

Final Voting Results

For	Against	Abstain	Broker Non-Vote
34,132,991	2,399,346	534,901	10,900

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICINOVA, INC.

By: /s/ Yuichi Iwaki

Yuichi Iwaki

President and Chief Executive Officer

Date: June 17, 2021